References
- Ward A, Clissold S P. Pentoxifylline: a review of its pharmaco-dynamic and pharmacokinetic properties and its therapeutic efficiency. Drugs 1987; 34: 50–97
- Honess D J, Dennis I F, Bleehen N M. Pentoxifylline: its phar-macokinetics and ability to improve tumour perfusion and radiosensitivity in mice. Radiother Oncol 1993; 28: 208–18
- Song C W, Hasegawa T, Kwon H C, Lyons J C, Levitt S H. Increase in tumor oxygenation and radiosensitivity caused by Pentoxifylline. Radiat Res 1992; 130: 205–10
- Lee I, Levitt S H, Song C W. Improved tumour oxygenation and radiosensitisation by combination with nicotinamide and Pentoxifylline. Int J Radiat Biol 1993; 64: 237–44
- Lee I, Boucher Y, Demhartner T J, Jain R K. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer 1994; 69: 492–6
- Twentyman P R, Brown M J, Gray J W, Franko A J, Scoles M A, Kallman R F. A new mouse tumour model system (RIF-1) for comparison of end point studies. J Natl Cancer Inst 1980; 64: 595–604
- UKCCCR. Guidelines for the welfare of animals in experimental neoplasia. UKCCCR, 20 Park Crescent, LondonU.K. 1988
- Sapirstein L A. Regional blood flow by fractional distribution of indicators. Am J Physiol 1958; 193: 161–8
- Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerised O2 tension measurements. Cancer Res 1991; 51: 3316–22